GRANULES

More in GRANULES

• Pharma company Granules India names KVS Ram Rao as Joint MD, CEO

  Rao has over two decades of experience in pharmaceutical and chemical industries.

  

• US FDA grants approval to Granules India for its generic Amphetamine Mixed Salts

  Amphetamine Mixed Salts IR tablets are prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

  

• Granules gets American drug regulator's nod for diabetes management drug Metformin

  The US Food and Drug Administration (USFDA) has granted final approval for the company's abbreviated new drug application (ANDA) for Metformin Hydrochloride extended-release tablets USP, 500 mg and 1000 mg, Granules said in a regulatory filing.

  

• Granules India gets USFDA approval for Butalbital, Acetaminophen, Caffeine capsules

  Butalbital, Acetaminophen and Caffeine Capsules are used to treat tension headaches.

  

• Granules gets USFDA nod for ADHD treatment drug

  The approved product is bioequivalent to the reference listed drug product (RLD), Ritalin LA extended-release capsules of Novartis Pharmaceuticals Corporation.

  

• Granules promoters sell 50 lakh shares in block deal

  The promoters had also reduced some amount of their personal loan in December 2018, which reduced their pledged stake from 60% to the current level of 54%.

  

• Granules Q2 net dips

  City-based pharma player Granules India on Thursday reported a marginal dip in net profit for the second quarter ended September 30, 2017, at Rs 40.33 crore as against Rs 40.82 crore in the corresponding quarter of last fiscal.

  

• Granules India gets EIR from USFDA for Vizag OmniChem facility

  OmniChem facility is operated by 50:50 joint venture of Granules India and Ajinimoto OmniChem N V, it said in a filing on BSE.

  

• No serious issues, or data integrity issues found during the inspection: C Krishna Prasad, CMD, Granules

  The observations will not have any impact and we are very happy with the outcome of the audit, added Prasad.

  

• Granules OmniChem unit under USFDA lens

  Granules OmniChem facility, a 50:50 joint venture company of Granules India Ltd and Ajinomoto OmniChem NV, located at Vizag completed its first inspection by USFDA with seven observations.